Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 11/20 | 0.58 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8242664 | 0.90 | TNKS (0.64) | TNKSTNKS2OPRM1PARP2PARP1 | |
| SCHEMBL16456031 | 0.86 | TNKS (0.64) | TNKSTNKS2OPRM1PARP2PARP1 | |
| SCHEMBL16456327 | 0.86 | TNKS (0.64) | TNKSTNKS2OPRM1PARP2PARP1 | |
| SCHEMBL20334018 | 0.85 | TNKS (0.59) | TNKSTNKS2OPRM1PARP2PARP1 | |
| SCHEMBL7178536 | 0.85 | TNKS (0.59) | TNKSTNKS2OPRM1PARP2PARP1 | |
| SCHEMBL15289117 | 0.84 | TNKS (0.59) | TNKSTNKS2OPRM1PARP2PARP1 | |
| SCHEMBL16445244 | 0.84 | TNKS (0.59) | TNKSTNKS2OPRM1PARP2PARP1 | |
| SCHEMBL7185339 | 0.84 | TNKS (0.59) | TNKSTNKS2OPRM1PARP2PARP1 | |
| SCHEMBL7185342 | 0.84 | TNKS (0.59) | TNKSTNKS2OPRM1PARP2PARP1 | |
| SCHEMBL7181965 | 0.84 | SIRT2 (0.60) | TNKSTNKS2OPRM1PARP2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340549-B2 | Oxazolidinone compounds and derivatives thereof | AMGEN INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN INC. | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | TNKS1BP1, TNKS, TBKBP1 | TNKS 2/4885TNKS2 10/4885OPRM1 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.